Zimmer Biomet Holdings stock (US98956P1021): shares trade near 52-week low

Zimmer Biomet Holdings opened lower on the NYSE on 06/01/2026, with the stock trading near its 52-week low as investors digest fresh holdings filings and a Hold consensus.

Zimmer Biomet Holdings shares were quoted at USD 82.46 on 06/01/2026 on the New York Stock Exchange, according to MarketBeat as of 06/01/2026. The move keeps the stock close to its 52-week low of USD 79.12 and below the 52-week high of USD 108.29, while MarketBeat also showed a consensus rating of Hold and an average price target of USD 102.70 on the same date.

For U.S. readers, the trading backdrop matters because Zimmer Biomet is listed on the NYSE under ZBH and remains firmly within the domestic large-cap medical technology universe. A fresh June 01, 2026 filings digest also highlighted changes in institutional holdings, including Geode Capital Management's increased position and Thompson Siegel & Walmsley's reduced stake, underscoring that the name is still drawing portfolio attention in the United States market.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Zimmer Biomet Holdings
• Sector/industry: Medical devices / medical equipment
• Headquarters/country: Warsaw, United States
• Core markets: United States, Europe, and other international medical technology markets
• Key revenue drivers: Orthopedic reconstruction, dental, and related musculoskeletal products
• Home exchange/listing venue: NYSE (ZBH)
• Trading currency: USD

Zimmer Biomet Holdings: core business model

Zimmer Biomet supplies medical devices for musculoskeletal care, with sales centered on implants and related products used in joint replacement, bone health, and other orthopedic procedures.

What banks and research houses say about Zimmer Biomet Holdings

The same MarketBeat page put the shares at USD 82.46 and showed a market capitalization of USD 15.95 billion, which frames the current valuation discussion for U.S. investors watching NYSE-listed healthcare names.

Conclusion

Zimmer Biomet enters the session with the shares still trading well below the MarketBeat consensus target, while the latest filing flow shows investors actively adjusting exposure. For U.S. market watchers, the combination of a near-52-week-low share price and a Hold consensus keeps attention on whether the stock can stabilize from here.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.